| Literature DB >> 35406693 |
Giorgia Centonze1, Sara Centonze2,3, Luca Ponzone1, Enzo Calautti1.
Abstract
Keratinocyte stem cells play a fundamental role in homeostasis and repair of stratified epithelial tissues. Transplantation of cultured keratinocytes autografts provides a landmark example of successful cellular therapies by restoring durable integrity in stratified epithelia lost to devastating tissue conditions. Despite the overall success of such procedures, failures still occur in case of paucity of cultured stem cells in therapeutic grafts. Strategies aiming at a further amplification of stem cells during keratinocyte ex vivo expansion may thus extend the applicability of these treatments to subjects in which endogenous stem cells pools are depauperated by aging, trauma, or disease. Pharmacological targeting of stem cell signaling pathways is recently emerging as a powerful strategy for improving stem cell maintenance and/or amplification. Recent experimental data indicate that pharmacological inhibition of two prominent keratinocyte signaling pathways governed by apical mTOR and ROCK protein kinases favor stem cell maintenance and/or amplification ex vivo and may improve the effectiveness of stem cell-based therapeutic procedures. In this review, we highlight the pathophysiological roles of mTOR and ROCK in keratinocyte biology and evaluate existing pre-clinical data on the effects of their inhibition in epithelial stem cell expansion for transplantation purposes.Entities:
Keywords: Rho-associated protein kinase (ROCK); Y-27632; cell therapy; keratinocyte stem cell; mammalian target of rapamycin (mTOR); rapamycin; regenerative medicine
Mesh:
Substances:
Year: 2022 PMID: 35406693 PMCID: PMC8997668 DOI: 10.3390/cells11071130
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Biological processes regulated by mTOR complexes and downstream effector pathways. Both mTORC1 and mTORC2 are activated downstream of growth factors binding to cell surface receptors, such as receptor tyrosine kinases (RTKs), while mTORC1 receives stimulatory inputs also by amino acids. The diagram reports mTOR binding partners within mTORC1 and mTORC2 as well as their best-established downstream effector molecules in the indicated biological processes. Within the nucleus, signaling molecules downstream of mTOR signaling regulate gene expression programs involved in glucose metabolism, lysosomal biogenesis, and lipid synthesis. The diagram includes the negative feedback emanating from the mTORC1 effector S6K1 on RTKs downstream signaling. The allosteric mTOR inhibitor rapamycin primarily inhibits mTORC1 but also mTORC2 upon prolonged exposure of cells to the drug.
Figure 2ROCK signaling in the regulation of cytoskeleton structure and dynamics.
Summary of the effects of mTOR and ROCK inhibitors in cultured Keratinocytes.
| Inhibitor | Cell Source | Feeder Layer | Effects on Cultured Cells | Article (First Author) |
|---|---|---|---|---|
| Rapamycin | Wnt1-overexpressing murine HFSCs | No | Reduced DNA damage, maintenance of stem cell markers | Castilho [ |
| Human oral keratinocytes | No | Increased clonogenicity and lifespan, protection from oxidative stress, reduced senescence, reduction of proliferation rate | Iglesias-Bartolome [ | |
| Human corneal epithelial cells | No | Increased clonogenicity and stem cell markers expression, reduced senescence and apoptosis, reduced proliferation rate | Gidfar [ | |
| Human skin keratinocytes | Yes | Reduced DNA methylation (epigenetic aging), reduced proliferation rate | Horvath [ | |
| Rapamycin, Torin, AZD8055 | Normal murine skin keratinocytes | No | Reduced expression of desmosomal proteins and loss of cell–cell adhesion | Asrani [ |
| Y-27632 | Rheb-KO and Raptor-KO murine skin keratinocytes | No | Rescue of adhesion defects caused by mTORC1 deficiency | Asrani [ |
| Porcine airway epithelial cells | No | Unlimited increase of lifespan | Dale [ | |
| Human skin keratinocytes | Yes | Unlimited increase of lifespan, increased cMyc expression, stabilization of telomeres length | Chapman [ | |
| Human skin keratinocytes | Yes | Increased proliferation rate | Horvath [ | |
| Human, bovine, and murine | Yes | Unlimited increase of lifespan, increased proliferation rate | Chapman [ | |
| Immortalized and normal human skin keratinocytes | Yes | Inhibition of clonal conversion | Nanba [ | |
| Human neonatal foreskin keratinocytes | No | Increased lifespan in low-calcium medium | Strudwick [ | |
| Human neonatal foreskin keratinocytes | Yes | Increased cellularity of colonies with gain of cell proliferation | Roshan [ | |
| Fasudil, HA1000, GSK429286 | Human skin keratinocytes | Yes | Unlimited increase of lifespan, increased proliferation rate | Chapman [ |
| Rapamycin | Human skin keratinocytes | Yes | Reduced DNA methylation (epigenetic aging), normal proliferation rate | Horvath [ |
Figure 3Summary of potential applications of rapamycin and Y-27632 in keratinocyte (stem cells) expansion for transplantation purposes. The diagram illustrates the normal process of clonal conversion and holoclone exhaustion occurring upon ex vivo expansion of keratinocytes isolated from patients’ stratified epithelia via a tissue biopsy. In the lower part of the figure are indicated advantages and disadvantages of the individual use of rapamycin and Y-27632 (see text and Table 1 for details) and the potential synergy of their combination for improving holoclone maintenance and expansion.